- Conditions
- Generalized Myasthenia Gravis
- Interventions
- zilucoplan (RA101495)
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 33
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Irvine, California + 29 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 85
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Myasthenia Gravis, Generalized
- Interventions
- Aritinercept, Placebo
- Drug · Other
- Lead sponsor
- Aurinia Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 11
- States / cities
- Pasadena, California • Altamonte Springs, Florida • Boca Raton, Florida + 7 more
- Conditions
- Myasthenia Gravis
- Interventions
- Nipocalimab, Placebo, Nipocalimab SC-LIV
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 24
- States / cities
- Paradise Valley, Arizona • Scottsdale, Arizona • Los Angeles, California + 21 more
- Conditions
- Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG), AChR-Ab Seropositive Generalized Myasthenia Gravis
- Interventions
- Efgartigimod IV, Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 12
- States / cities
- Carlsbad, California • Miami, Florida • Tampa, Florida + 8 more
- Conditions
- Generalized Myasthenia Gravis, Myasthenia Gravis
- Interventions
- ALXN2050, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Boca Raton, Florida + 14 more
- Conditions
- Myasthaenia Gravis, Myasthenia, Myasthenia Gravis Associated with Thymoma, Myasthenia Gravis Crisis, Myasthenia Gravis Exacerbations, Myasthenia Gravis Generalised, Myasthenia Gravis with Exacerbation (Disorder), Myasthenia Gravis, Adult Form, Myasthenia Gravis, Generalized, Myasthenia Gravis, Ocular, Myasthenia Gravis, Thymectomy, Myasthenia Gravis, Myasthenia Gravis, MuSK
- Interventions
- Not listed
- Lead sponsor
- Myasthenia Gravis Foundation of America
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2029
- U.S. locations
- 1
- States / cities
- Westborough, Massachusetts
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Efgartigimod IV
- Biological
- Lead sponsor
- argenx
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Chapel Hill, North Carolina • Charlottesville, Virginia
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- ARGX-113
- Biological
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 14
- States / cities
- Carlsbad, California • Los Angeles, California • Orange, California + 11 more
- Conditions
- Myasthenia Gravis, Myasthenia Gravis, Generalized
- Interventions
- Not listed
- Lead sponsor
- BioSensics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Myasthenia Gravis, Generalized
- Interventions
- Descartes-08
- Drug
- Lead sponsor
- Cartesian Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 14
- States / cities
- Carlsbad, California • Irvine, California • Aurora, Colorado + 11 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Zilucoplan
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Flower Mound, Texas
- Conditions
- Myasthenia Gravis, Myasthenia Gravis, Generalized
- Interventions
- No intervention
- Other
- Lead sponsor
- ProgenaBiome
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 1
- States / cities
- Ventura, California
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- efgartigimod PH20 SC, efgartigimod IV
- Biological
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 14
- States / cities
- Carlsbad, California • Orange, California • Boca Raton, Florida + 11 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Placebo, Cladribine Low Dose, Cladribine High Dose
- Other · Drug
- Lead sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Longmont, Colorado • Farmington, Connecticut + 18 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Rozanolixizumab
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Orange, California • San Francisco, California • Lexington, Kentucky + 1 more
- Conditions
- AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG), MG - Myasthenia Gravis, gMG
- Interventions
- Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS
- Biological · Other · Combination Product
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Miami, Florida • Amherst, New York • Chattanooga, Tennessee
- Conditions
- Myasthenia Gravis Generalised
- Interventions
- mycophenolate mofetil [CellCept], Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 3
- States / cities
- Sun City, Arizona • Sacramento, California • Upland, Pennsylvania
- Conditions
- Myasthenia Gravis, Generalized Myasthenia Gravis
- Interventions
- Standard of Care Treatment, Standard lymphodepletion regimen, KYV-101
- Drug · Biological
- Lead sponsor
- Kyverna Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Orange, California • Palo Alto, California + 7 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- YTB323
- Genetic
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- Orange, California • Winston-Salem, North Carolina • Philadelphia, Pennsylvania + 1 more
- Conditions
- Refractory Generalized Myasthenia Gravis
- Interventions
- Eculizumab, Placebo
- Biological · Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Fresno, California • Los Angeles, California + 35 more
- Conditions
- Myasthenia Gravis, Generalized
- Interventions
- Povetacicept, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 15
- States / cities
- Mission Hills, California • Boca Raton, Florida • Homestead, Florida + 10 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Rozanolixizumab
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 13
- States / cities
- Orange, California • San Francisco, California • Miami, Florida + 9 more
- Conditions
- Multiple Sclerosis, Myasthenia Gravis
- Interventions
- CC-97540, Fludarabine, Cyclophosphamide
- Drug
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Irvine, California • Aurora, Colorado + 12 more
- Conditions
- Generalized Myasthenia Gravis, gMG
- Interventions
- Efgartigimod IV or Efgartigimod PH20 SC
- Biological
- Lead sponsor
- argenx
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Charlotte, North Carolina • Charlottesville, Virginia